AbbVie (NYSE:ABBV) EVP Nicholas Donoghoe Sells 32,710 Shares of Stock

AbbVie Inc. (NYSE:ABBV) EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

AbbVie Stock Up 3.5%

Shares of ABBV stock opened at $259.01 on Wednesday. The stock has a market cap of $457.63 billion, a P/E ratio of 73.17, a PEG ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The company’s fifty day simple moving average is $246.17 and its two-hundred day simple moving average is $226.63.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s payout ratio is presently 195.48%.

Analyst Ratings Changes

Several equities analysts have recently commented on ABBV shares. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. UBS Group boosted their price objective on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, July 13th. HSBC reaffirmed a “buy” rating and issued a $300.00 price target on shares of AbbVie in a report on Monday, July 6th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a report on Thursday, August 13th. Finally, BNP Paribas Exane boosted their price objective on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $275.73.

Institutional Investors Weigh In On AbbVie

Several hedge funds have recently bought and sold shares of ABBV. Pin Oak Investment Advisors Inc. bought a new stake in shares of AbbVie during the 2nd quarter valued at $613,000. 49 Wealth Management LLC acquired a new stake in shares of AbbVie during the second quarter worth approximately $2,729,000. Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in AbbVie by 7.6% during the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 167,270 shares of the company’s stock worth $42,018,000 after purchasing an additional 11,800 shares during the last quarter. Rakuten Investment Management Inc. raised its holdings in AbbVie by 10.2% during the 2nd quarter. Rakuten Investment Management Inc. now owns 289,091 shares of the company’s stock worth $73,519,000 after purchasing an additional 26,793 shares during the last quarter. Finally, RB Capital Management LLC boosted its position in AbbVie by 1.4% during the second quarter. RB Capital Management LLC now owns 15,124 shares of the company’s stock worth $3,806,000 after purchasing an additional 208 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.